Get the Stockscreener App
1.43
2.14%
0.03
After Hours:
1.44
0.01
+0.70%
Cardiol Therapeutics Inc stock is traded at $1.43, with a volume of 439.49K.
It is up +2.14% in the last 24 hours and up +40.20% over the past month.
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
See More
Previous Close:
$1.40
Open:
$1.39
24h Volume:
439.49K
Relative Volume:
0.78
Market Cap:
$159.70M
Revenue:
-
Net Income/Loss:
$-24.22M
P/E Ratio:
-5.109
EPS:
-0.2799
Net Cash Flow:
$-17.13M
1W Performance:
+10.85%
1M Performance:
+40.20%
6M Performance:
+32.41%
1Y Performance:
+34.91%
1-Day Range:
$1.375
$1.44
1-Week Range:
$1.29
$1.46
52-Week Range:
$0.88
$1.59
Cardiol Therapeutics Inc Stock (CRDL) Company Profile
Compare CRDL vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRDL
Cardiol Therapeutics Inc
|
1.43 | 156.35M | 0 | -24.22M | -17.13M | -0.2799 |
TAK
Takeda Pharmaceutical Co Adr
|
17.85 | 56.39B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
120.76 | 50.93B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.66 | 43.19B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.61 | 36.99B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
577.58 | 25.36B | 3.18B | 1.33B | 1.04B | 27.90 |
Cardiol Therapeutics Inc Stock (CRDL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Initiated | H.C. Wainwright | Buy |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jun-26-24 | Initiated | ROTH MKM | Buy |
| Apr-22-24 | Initiated | H.C. Wainwright | Buy |
Cardiol Therapeutics Inc Stock (CRDL) Latest News
Cardiol Therapeutics CEO: Phase III MAVERIC Nears Full Enrollment as CardiolRx Shows Myocarditis Promise - Yahoo Finance
Cardiol Therapeutics CEO to discuss drug trials in interview By Investing.com - Investing.com Canada
Cardiol Therapeutics Showcases MAVERIC Phase III Trial and ARCHER Results in Barchart Live Interview - TipRanks
Cardiol Therapeutics Inc. - Baystreet.ca
Cardiol Therapeutics (CRDL) CEO to discuss MAVERIC, ARCHER and CRD-38 in X interview - Stock Titan
Cardiol CEO goes live on X to discuss Phase III heart drug trial - Stock Titan
Cardiol Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
$30 Billion Per Year US Heart Failure Market Presents Huge Opportunity for Promising Drugs Advancing with Positive Trial Results for Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) - Barchart.com
Top Athira Pharma (LONA) Competitors 2026 - MarketBeat
Earnings Report: Is Cardiol Therapeutics Inc a cyclical or defensive stock2026 Pullback Review & High Yield Equity Trading Tips - baoquankhu1.vn
Cardiol Therapeutics Sets June 24, 2026 Date for Annual General Meeting of Shareholders - The Globe and Mail
3 Biotech Stocks Surge with Momentum - National Today
Cardiol Therapeutics (CRDL) sets June 24, 2026 AGM and May 7 record date - Stock Titan
Risk Off: Should I trade or invest in Cardiol Therapeutics Inc2026 Biggest Moves & Precise Trade Entry Recommendations - baoquankhu1.vn
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE), Alzamend Neuro (ALZN) and Cardiol Therapeutics (CRDL) - The Globe and Mail
CRDL Stock Price, Quote & Chart | CARDIOL THERAPEUTICS INC-A (NASDAQ:CRDL) - ChartMill
CRDL Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Cardiol Therapeutics (CRDL) Receives 'Buy' Rating from Canaccord Genuity | CRDL Stock News - GuruFocus
Cardiol Therapeutics (NASDAQ:CRDL) Earns "Buy" Rating from Canaccord Genuity Group - MarketBeat
Cardiol Therapeutics (NASDAQ:CRDL) Raised to Hold at Wall Street Zen - MarketBeat
CRDL SEC FilingsCardiol Therapeu 10-K, 10-Q, 8-K Forms - Stock Titan
What is HC Wainwright's Estimate for CRDL FY2028 Earnings? - MarketBeat
CARDIOL THERAPEUTICS INC (CRDL.NE) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Cardiol Therapeutics Inc. (CA14161Y2006.SG) insider ownership and holdings - Yahoo Finance UK
Cardiol surpasses 50% enrollment in phase III pericarditis trial By Investing.com - Investing.com South Africa
Merger Talk: Will Cardiol Therapeutics Inc outperform the market in YEAR2026 Analyst Calls & High Accuracy Investment Signals - baoquankhu1.vn
Cardiol Therapeutics (NASDAQ:CRDL) Posts Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
Cardiol Therapeutics Details 2025 Progress and Funding for Late-Stage Cardiac Drug Programs - TipRanks
Cardiol Therapeutics initiated pivotal Phase III Maveric trial of Cardiolrx in recurrent pericarditis - marketscreener.com
Cardiol Therapeutics Initiated Pivotal Phase Iii Maveric Trial Of Cardiolrx In Recurrent Pericarditis - TradingView
Cardiol surpasses 50% enrollment in phase III pericarditis trial - Investing.com
Cardiol Therapeutics (NASDAQ: CRDL) advances 2025 cardiac trials and funding - Stock Titan
Heart drug trial passes halfway mark as Cardiol funds work into 2027 - Stock Titan
Cardiol Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Cardiol Therapeutics Achieves MAVERIC Enrollment Milestone Amidst Approaching Cash Runway Deadline - Bitget
Cardiol Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Cardiol Therapeutics (CRDL) files Form 40-F: 100.26M shares, audited 2025 results - Stock Titan
Cardiol Therapeutics Inc expected to post a loss of 10 cents a shareEarnings Preview - TradingView — Track All Markets
Fed Meeting: Can Cardiol Therapeutics Inc maintain its current growth rateWeekly Profit Recap & Technical Buy Zone Confirmation - baoquankhu1.vn
Cardiol Therapeutics (TSE:CRDL) Trading Up 10.5%Time to Buy? - MarketBeat
Earnings Recap: Can Cardiol Therapeutics Inc maintain its current growth rate2026 Analyst Calls & Community Consensus Trade Alerts - baoquankhu1.vn
Total debt of Cardiol Therapeutics Inc. Class A – HAM:CT9 - TradingView
Free cash flow of Cardiol Therapeutics Inc. Class A – HAM:CT9 - TradingView
Operating income of Cardiol Therapeutics Inc. Class A – HAM:CT9 - TradingView
Taxes of Cardiol Therapeutics Inc. Class A – HAM:CT9 - TradingView
Cardiol Therapeutics (CRDL) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Cardiol Therapeutics (TSX:CRDL) Expands Research Scope In Tsx Small Cap Index - Kalkine Media
If You Invested $1,000 in Cardiol Therapeu (CRDL) - Stock Titan
Cardiol Therapeutics (TSE:CRDL) Shares Down 1.5%Time to Sell? - MarketBeat
Cizzle Brands Corporation Releases Fiscal Q2 2026 Results - Investing News Network
Cardiol Therapeutics Inc Stock (CRDL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.45%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):